Only with the aid of clinical trials is it possible to ascertain how to improve efficacy and collect data on the impact of adverse effects. Every well-conducted study, every participating site and patient contribute to improved care for tumor patients.
If you are interested in participating in a study, please don’t hesitate to contact us.
HR+/HER2-
Waldenström macroglobulinemia
metastasized
metastasized, BRAFV600E-mutation
Renal Cell Carcinoma
metastatic / locally advanced and inoperable
CLL
Locally advanced, unresectable or metastatic solid tumour
NSCLC, stage II - IV
Newly diagnosed, not suitable for autologous SCT
HR+/HER2-HR+/HER2-locally advanced, unresectable or metastatic
Solid tumor with NTRK gene fusion, locally advanced or metastatic
metastatic
r/r MM
FIGO Stadium IIb-I
FIGO Stadium III-IV
metastatic / advanced and inoperable
metastatic, RAS wild-type